Skip to main content
. 2019 Feb 6;6(3):e154–e166. doi: 10.1016/S2352-3026(18)30220-5

Figure 4.

Figure 4

Kaplan-Meier curves for overall survival by MRP groups in patients receiving combinations without immunomodulatory drugs

(A) CVD consolidation therapy in NCRI Myeloma XI (NCRI-XI; n=157). (B) Melphalan plus prednisolone in MRC Myeloma IX (MRC-IX; n=272). CVD=cyclophosphamide, bortezomib, and dexamethasone. MRP=UK Myeloma Research Alliance Risk Profile. NR=not reached.